It's a matter of perspective. He asked what the results would be for Remdesivir without Brilacidin.
Remdesivir wouldn't be described as bleak by Gilead or its shareholders. Quite the opposite actually. Only a COVID patient would describe it that way.
The answer is Remdesivir results are great for Gilead with or without Brilacidin. It has yielded over a billion dollars in profit for the company. Anything else is just gravy. It will likely harvest another billion before a true competitor comes on stage.
News 
Market Data 
Discover 
